A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Aldesleukin (Primary) ; PNK 007 (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation; Celularity
- 27 Feb 2018 Planned number of patients changed from 40 to 46.
- 27 Feb 2018 Planned End Date changed from 30 Nov 2018 to 30 Apr 2020.
- 27 Feb 2018 Planned primary completion date changed from 30 Nov 2018 to 30 Apr 2020.